Concert Pharmaceuticals Inc. (NASDAQ:CNCE) traded down 0% during trading on Friday . The stock traded as low as $11.56 and last traded at $11.79, with a volume of 51,884 shares traded. The stock had previously closed at $11.79.

Several equities research analysts recently commented on the stock. Zacks Investment Research lowered shares of Concert Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Tuesday, May 10th. Brean Capital reiterated a “buy” rating on shares of Concert Pharmaceuticals in a research report on Saturday, April 30th. Finally, Stifel Nicolaus assumed coverage on shares of Concert Pharmaceuticals in a research report on Friday, July 1st. They issued a “buy” rating and a $23.00 price objective on the stock. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and six have assigned a buy rating to the company. Concert Pharmaceuticals has an average rating of “Buy” and an average target price of $26.43.

The firm’s 50-day moving average is $12.16 and its 200 day moving average is $13.84. The stock has a market capitalization of $262.15 million and a price-to-earnings ratio of 14.17.

Concert Pharmaceuticals (NASDAQ:CNCE) last announced its quarterly earnings data on Thursday, May 5th. The company reported ($0.63) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.45) by $0.18. Equities analysts forecast that Concert Pharmaceuticals Inc. will post ($2.57) EPS for the current fiscal year.

In related news, CEO Roger D. Tung purchased 19,610 shares of the firm’s stock in a transaction that occurred on Wednesday, May 11th. The shares were acquired at an average price of $10.55 per share, with a total value of $206,885.50. Following the purchase, the chief executive officer now directly owns 538,965 shares in the company, valued at $5,686,080.75. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.

A hedge fund recently raised its stake in Concert Pharmaceuticals stock. California Public Employees Retirement System boosted its position in Concert Pharmaceuticals Inc. (NASDAQ:CNCE) by 22.0% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 103,700 shares of the company’s stock after buying an additional 18,700 shares during the period. California Public Employees Retirement System owned about 0.47% of Concert Pharmaceuticals worth $1,967,000 as of its most recent SEC filing.

Concert Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery and development of small molecule drugs. The Company operates through the development of pharmaceutical products on its own behalf or in collaboration with others segment. It has clinical candidates under development, including AVP-786, CTP-656, CTP-730 and JZP-386.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.